IOVA Long Call Strategy

IOVA (Iovance Biotherapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.

IOVA (Iovance Biotherapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.31B, a beta of 0.69 versus the broader market, a 52-week range of 1.64-5.63, average daily share volume of 17.3M, a public-listing history dating back to 2010, approximately 838 full-time employees. These structural characteristics shape how IOVA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.69 indicates IOVA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long call on IOVA?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current IOVA snapshot

As of May 15, 2026, spot at $3.46, ATM IV 97.43%, IV rank 16.40%, expected move 27.93%. The long call on IOVA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this long call structure on IOVA specifically: IOVA IV at 97.43% is on the cheap side of its 1-year range, which favors premium-buying structures like a IOVA long call, with a market-implied 1-standard-deviation move of approximately 27.93% (roughly $0.97 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IOVA expiries trade a higher absolute premium for lower per-day decay. Position sizing on IOVA should anchor to the underlying notional of $3.46 per share and to the trader's directional view on IOVA stock.

IOVA long call setup

The IOVA long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IOVA near $3.46, the first option leg uses a $3.46 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IOVA chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IOVA shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$3.46N/A

IOVA long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

IOVA long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on IOVA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on IOVA

Long calls on IOVA express a bullish thesis with defined risk; traders use them ahead of IOVA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

IOVA thesis for this long call

The market-implied 1-standard-deviation range for IOVA extends from approximately $2.49 on the downside to $4.43 on the upside. A IOVA long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current IOVA IV rank near 16.40% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IOVA at 97.43%. As a Healthcare name, IOVA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IOVA-specific events.

IOVA long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IOVA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IOVA alongside the broader basket even when IOVA-specific fundamentals are unchanged. Long-premium structures like a long call on IOVA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current IOVA chain quotes before placing a trade.

Frequently asked questions

What is a long call on IOVA?
A long call on IOVA is the long call strategy applied to IOVA (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With IOVA stock trading near $3.46, the strikes shown on this page are snapped to the nearest listed IOVA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are IOVA long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the IOVA long call priced from the end-of-day chain at a 30-day expiry (ATM IV 97.43%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a IOVA long call?
The breakeven for the IOVA long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IOVA market-implied 1-standard-deviation expected move is approximately 27.93%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on IOVA?
Long calls on IOVA express a bullish thesis with defined risk; traders use them ahead of IOVA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current IOVA implied volatility affect this long call?
IOVA ATM IV is at 97.43% with IV rank near 16.40%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related IOVA analysis